{"id":"W4412521280","doi":"10.1016/j.annonc.2025.07.003","title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; EMD Serono; Genentech; Sierra Oncology; Amgen; Siemens Healthineers; Astellas Pharma; Eisai; AstraZeneca; Invitae; MacroGenics; Y-mAbs Therapeutics; UroGen Pharma; Ipsen; BeiGene; National Institutes of Health; Menarini Silicon Biosystems; Vertex Pharmaceuticals; Boston Scientific Corporation; Sanofi; Endocyte; Novartis; Cardinal Health; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Hazard ratio; Progression-free survival; Abiraterone acetate; Taxane; Adverse effect; Oncology; Randomized controlled trial; Urology; Androgen receptor; Confidence interval; Androgen deprivation therapy; Chemotherapy; Cancer; Breast cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004296068,0.001453868,0.002485175,0.0005947018,0.0004590785,0.001580537,0.001034601,0.001281148,0.004413031],"category_scores_gemma":[0.002315686,0.0005317564,0.004116938,0.00055549,0.001051722,0.001328723,0.0004827876,0.004176723,0.0008777116],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001415637,"about_ca_system_score_gemma":0.001761848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001477133,"about_ca_topic_score_gemma":0.00389064,"domain_scores_codex":[0.998629,0.0008194243,0.00005100555,0.0001559501,0.0001073289,0.0002373745],"domain_scores_gemma":[0.9979918,0.0006211951,0.0004332437,0.0002232371,0.0001279776,0.000602535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9142372,0.007869007,0.00818341,0.0004338713,0.005395398,0.000122629,0.0001520057,0.008032365,0.01079974,0.0005405737,0.004025704,0.04020808],"study_design_scores_gemma":[0.5054651,0.3983926,0.06462053,0.00009153819,0.008559936,0.0004197188,0.0002296361,0.007861904,0.006644888,0.0021925,0.005410095,0.0001114993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882754,0.002319428,0.0008694339,0.0005814598,0.0001442336,0.0005688818,0.003348389,0.00009259369,0.003800215],"genre_scores_gemma":[0.9885314,0.0007749327,0.0007873576,0.0006654376,0.0001526335,0.0005191406,0.005505574,0.00007097133,0.002992613],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004413031,"threshold_uncertainty_score":0.02272004,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1955177668737525,"score_gpt":0.4526475834852379,"score_spread":0.2571298166114854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}